This retrospective study evaluated the effects of perioperative treatment options in 126 patients with diffuse malignant peritoneal mesothelioma (DMPM) undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). The 5-year overall survival was significantly different among the perioperative treatment groups: 40% in patients receiving neoadjuvant chemotherapy, 67% in patients receiving adjuvant chemotherapy, 62% in patients receiving perioperative chemotherapy, and 56% in patients receiving no chemotherapy before or after CRS-HIPEC. Major complications occurred in approximately 40% of patients in each group. Worse overall survival was significantly associated with receiving neoadjuvant chemotherapy (HR, 2.30; 95% CI, 1.07–4.94; P = .033).
This study suggests that neoadjuvant chemotherapy may decrease overall survival while adjuvant chemotherapy may improve survival in patients with DMPM who undergo CRS-HIPEC.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.